3rd Quarter - Amendment

GILEAD SCIENCES, INC. for GILEAD SCIENCES INC

Firm
Client
Income
—
Expenses
$2,320,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 20, 2026 $6,580,000 Replaced
3rd Quarter - Amendment (this page) Oct 21, 2026 $2,320,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.

LobbyistCovered position, as disclosed
BILL BODE —
MICHAEL D BOYD —
JAIMON JACKSON —
DAVID PULLIAM —
GRACE RODDEN —
RILEY SWINEHART —
RICHARD WHITE —

Contacted: State, Dept of (DOS); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Budget/Appropriations BUD

Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.

LobbyistCovered position, as disclosed
BILL BODE —
JAIMON JACKSON —
DAVID PULLIAM —
GRACE RODDEN —
RILEY SWINEHART —
RICHARD WHITE —

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; White House Office; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.

LobbyistCovered position, as disclosed
BILL BODE —
MICHAEL D BOYD —
ANNA GRIFFIN —
JAIMON JACKSON —
DAVID PULLIAM —
GRACE RODDEN —
RILEY SWINEHART —
RICHARD WHITE —

Contacted: HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); State, Dept of (DOS); Commerce, Dept of (DOC); Centers For Disease Control & Prevention (CDC); SENATE; Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.

LobbyistCovered position, as disclosed
BILL BODE —
MICHAEL D BOYD —
ANNA GRIFFIN —
JAIMON JACKSON —
DAVID PULLIAM —
GRACE RODDEN —
RILEY SWINEHART —
RICHARD WHITE —

Contacted: White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Copyright/Patent/Trademark CPT

Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.

LobbyistCovered position, as disclosed
BILL BODE —
DAVID PULLIAM —
GRACE RODDEN —
RICHARD WHITE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO)

Taxation/Internal Revenue Code TAX

Legislative and regulatory proposals to change international and domestic corporate tax law and policy.

LobbyistCovered position, as disclosed
DAVID PULLIAM —
GRACE RODDEN —

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Treasury, Dept of; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.